Flexeril
This article was originally published in The Tan Sheet
Executive Summary
OTC rights retained by Merck under transaction divesting Rx sales and marketing rights for the muscle relaxant and exclusive trademark rights in the U.S. and Canada to Alza. Merck receives up-front and milestone payments under deal. Alza currently is developing a once-a-day formulation of cyclobenzaprine. Merck says it is continuing discussions with FDA about switching Flexeril OTC. In July 1999, NDAC expressed concerns about patients' ability to accurately detect when to use OTC Flexeril 5 mg but did not take a formal vote on a switch (1"The Tan Sheet" July 26, 1999, p. 3)
You may also be interested in...
Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee
The ability of patients to accurately detect when they would need to use Flexeril 5 mg (cyclobenzaprine) is a significant hurdle the drug would need to overcome in a switch from the Rx to the OTC environment, according to discussions by FDA's Nonprescription Drugs and Arthritis Advisory Committees July 20.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands